{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:37:08Z","timestamp":1789591028737,"version":"build-2803163510"},"reference-count":15,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2006,1,27]],"date-time":"2006-01-27T00:00:00Z","timestamp":1138320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2006,3]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold>The impact of variant Creutzfeldt\u2013Jakob disease (vCJD) on the clinical practice of haemophilia in the UK is coloured by the haemophilia community's experience of hepatitis C virus and human immunodeficiency virus (HIV) transmission via plasma\u2010derived therapies in the 1980s, when the delay in recognizing and acting on the potential risks cost many patients their lives and left others to manage another chronic disease. This crisis prompted organisations such as the United Kingdom Haemophilia Centre Doctors\u2019 Organisation to advocate for the introduction of haemophilia therapies that would not be susceptible to contamination with blood\u2010borne pathogens. After the identification of vCJD in 1996, a number of public health measures were taken in response to a government\u2010sponsored vCJD risk assessment, and following reports of transfusion\u2010transmission of vCJD, additional guidelines have been developed to prevent person\u2010to\u2010person transmission, some of which may impact the quality and availability of medical and surgical care. Variant CJD has had a significant negative effect on the UK haemophilia community, shaking patient confidence in the therapies they have received over the last 21\u2003years, affecting the quality of care and creating the risk of stigmatizing the community as it was in the 1980s. As with HIV and vCJD, emerging blood\u2010borne infectious agents will likely affect blood and blood\u2010derived therapies well before we become aware of its presence. As a result, only therapies with the lowest level of risk should be used for care of patients with haemophilia.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2006.01196.x","type":"journal-article","created":{"date-parts":[[2006,1,27]],"date-time":"2006-01-27T15:58:16Z","timestamp":1138377496000},"page":"16-20","source":"Crossref","is-referenced-by-count":9,"title":["Clinical implications of emerging pathogens in haemophilia: the variant Creutzfeldt\u2013Jakob disease experience"],"prefix":"10.1111","volume":"12","author":[{"given":"G.","family":"DOLAN","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,1,27]]},"reference":[{"key":"e_1_2_11_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1997.00073.x"},{"key":"e_1_2_11_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2004.04029.x"},{"key":"e_1_2_11_4_2","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1160\/TH04-04-0229","article-title":"Contamination of coagulation factor concentrates with human parvovirus B19 genotype 1 and 2","volume":"92","author":"Schneider B","year":"2004","journal-title":"Thromb Haemost"},{"key":"e_1_2_11_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)64307-3"},{"key":"e_1_2_11_6_2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.55782\/ane-2002-1435","article-title":"Variant Creutzfeldt\u2013Jakob disease","volume":"62","author":"Will RG.","year":"2002","journal-title":"Acta Neurobiol Exp"},{"key":"e_1_2_11_7_2","volume-title":"Provision of Recombinant Factor VIII for New Patients and Children Under the Age of 16","author":"National Health Service"},{"key":"e_1_2_11_8_2","volume-title":"vCJD and Plasma Products \u2013 Tables of vCJD Implicated Batch Numbers: To Those Responsible for Tracing vCJD Implicated Plasma Product Batches in the UK","author":"Health Protection Agency"},{"key":"e_1_2_11_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15486-X"},{"key":"e_1_2_11_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16811-6"},{"key":"e_1_2_11_11_2","volume-title":"Risk Assessment of Exposure to vCJD Infectivity in Blood and Blood Products","author":"Det Norske Veritas for Department of Health"},{"key":"e_1_2_11_12_2","volume-title":"vCJD and Plasma Products \u2013 Clinical Information","author":"Health Protection Agency"},{"key":"e_1_2_11_13_2","volume-title":"Risk Assessment for Transmission of vCJD via Surgical Instruments: a Modelling Approach and Numerical Scenarios","author":"Department of Health, Economics and Operational Research Division (EOR4)"},{"key":"e_1_2_11_14_2","volume-title":"Transmissible Spongiform Encephalopathy Agents: Safe Working and the Prevention of Infection","author":"Advisory Committee on Dangerous Pathogens and the Spongiform Encephalopathy Advisory Committee","year":"2003"},{"key":"e_1_2_11_15_2","volume-title":"Transmissible Spongiform Encephalopathy Agents: Safe Working and the Prevention of Infection","author":"Advisory Committee on Dangerous Pathogens and the Spongiform Encephalopathy Advisory Committee","year":"2003"},{"key":"e_1_2_11_16_2","volume-title":"Transmissible Spongiform Encephalopathy Agents: Safe Working and the Prevention of Infection","author":"Advisory Committee on Dangerous Pathogens and the Spongiform Encephalopathy Advisory Committee","year":"2003"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2006.01196.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2006.01196.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T16:08:44Z","timestamp":1706890124000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2006.01196.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,27]]},"references-count":15,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["10.1111\/j.1365-2516.2006.01196.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2006.01196.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,27]]}}}